Low mortality rate in a large cohort of myelin oligodendrocyte glycoprotein antibody disease (MOGAD)

The mortality rates of individuals with myelin oligodendrocyte glycoprotein antibody disease (MOGAD) are currently unknown. This study aimed to assess the mortality rate in a large cohort of patients with MOGAD. Since none of the patients in our cohort died, we estimated the upper limit of a 95% con...

Descripción completa

Detalles Bibliográficos
Autores principales: Lotan, Itay, Romanow, Gabriela, Salky, Rebecca, Molazadeh, Negar, Vishnevetsky, Anastasia, Anderson, Monique, Bilodeau, Philippe Antoine, Cutter, Gary, Levy, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109314/
https://www.ncbi.nlm.nih.gov/pubmed/36852731
http://dx.doi.org/10.1002/acn3.51750
Descripción
Sumario:The mortality rates of individuals with myelin oligodendrocyte glycoprotein antibody disease (MOGAD) are currently unknown. This study aimed to assess the mortality rate in a large cohort of patients with MOGAD. Since none of the patients in our cohort died, we estimated the upper limit of a 95% confidence interval of the crude mortality rate in the cohort to be 2.1%. These data suggest that mortality in MOGAD is lower than that reported in other neuroinflammatory diseases and comparable to the age‐adjusted mortality rates of the general population in the United States. Additional studies are warranted to confirm this observation.

Ejemplares similares